Skip to main content

Table 2 Changes in blood glucose, pancreatic beta cell function and insulin resistance over 48 weeks on dolutegravir in the study participants

From: Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

Time point

Fasting blood glucose

2-hour OGTT glucose

Pancreatic beta cell

function (HOMA %β)

Insulin resistance

(HOMA IR)

 

Mean (95% CI)

Mean (95% CI)

Mean (95% CI)

Mean (95% CI)

Baseline

90.1 (87.6, 92.6)

115.9 (108.8, 122.9)

65.1 (50.6, 79.7)

1.05 (0.54, 1.56)

Week 12

86.8 (84.8, 88.8)

101.3 (96.4, 106.2)

90.8 (78.5, 103.2)

1.33 (1.04, 1.61)

Difference

-3.3 (-6.0, -0.5)

-14.6 (-22.1, -7.0)

24.9 (6.3, 43.6)

0.27 (-0.24, 0.79)

p-value

0.020

0.0003

0.010

0.294

Week 24

89.2 (87.3, 91.1)

   

Difference

-0.8 (-3.3, 1.6)

   

p-value

0.497

   

Week 36

91.2 (89.3, 93.1)

110.4 (105.9, 114.9)

75.1 (61.5, 88.6)

1.27 (0.90, 1.64)

Difference

1.2 (-1.7, 4.1)

-5.1 (-12.4, 2.1)

8.8 (-13.2, 30.7)

0.22 (-0.44, 0.87)

p-value

0.414

0.163

0.427

0.511

Week 48

90.5 (88.5, 92.4)

 

73.6 (61.0, 86.1)

1.19 (0.85, 1.53)

Difference

0.4 (-2.2, 3.1)

 

6.7 (-13.4, 26.8)

0.14 (-0.46, 0.733)

p-value

0.742

 

0.506

0.648

  1. OGTT- oral glucose tolerance test, HOMA %β- Homeostatic modeling for pancreatic beta cell function, HOMA IR- Homeostatic modelling for insulin resistance, CI- confidence interval